Mirum Pharmaceuticals IncNASDAQ:MIRM
- LAST PRICE19.9800
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0000/ 0
- Ask / Lots27.2000/ 28
- Open / Previous Close19.3600 / 19.9800
- Day Range
- 52 Week Range
- Volume76,570
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MIRM |
|---|---|---|
| 09:32 ET | 441 | 19.36 |
| 09:34 ET | 521 | 19.35 |
| 09:36 ET | 600 | 19.1315 |
| 09:41 ET | 474 | 19.46 |
| 09:52 ET | 723 | 19.645 |
| 09:56 ET | 1692 | 19.65 |
| 09:57 ET | 800 | 19.65 |
| 10:03 ET | 100 | 19.62 |
| 10:06 ET | 400 | 19.57 |
| 10:30 ET | 100 | 19.31 |
| 10:35 ET | 100 | 19.35 |
| 10:39 ET | 300 | 19.29 |
| 10:46 ET | 414 | 19.28 |
| 10:50 ET | 200 | 19.38 |
| 10:55 ET | 400 | 19.34 |
| 10:57 ET | 200 | 19.44 |
| 11:06 ET | 300 | 19.46 |
| 11:08 ET | 900 | 19.49 |
| 11:09 ET | 400 | 19.63 |
| 11:20 ET | 100 | 19.79 |
| 11:26 ET | 100 | 19.74 |
| 11:42 ET | 200 | 19.78 |
| 11:45 ET | 100 | 19.78 |
| 11:47 ET | 100 | 19.75 |
| 11:51 ET | 100 | 19.72 |
| 11:58 ET | 5045 | 19.74 |
| 12:02 ET | 500 | 19.7 |
| 12:03 ET | 200 | 19.66 |
| 12:05 ET | 200 | 19.65 |
| 12:07 ET | 200 | 19.71 |
| 12:21 ET | 100 | 19.74 |
| 12:30 ET | 100 | 19.69 |
| 12:36 ET | 100 | 19.66 |
| 12:43 ET | 200 | 19.59 |
| 12:50 ET | 100 | 19.55 |
| 12:52 ET | 100 | 19.6 |
| 01:01 ET | 100 | 19.555 |
| 01:03 ET | 5694 | 19.46 |
| 01:06 ET | 100 | 19.45 |
| 01:08 ET | 200 | 19.41 |
| 01:12 ET | 200 | 19.35 |
| 01:15 ET | 700 | 19.41 |
| 01:26 ET | 100 | 19.36 |
| 01:30 ET | 300 | 19.41 |
| 01:39 ET | 100 | 19.45 |
| 01:46 ET | 120 | 19.46 |
| 01:48 ET | 401 | 19.45 |
| 01:51 ET | 100 | 19.51 |
| 01:53 ET | 100 | 19.55 |
| 02:08 ET | 136 | 19.541 |
| 02:15 ET | 100 | 19.57 |
| 02:20 ET | 690 | 19.575 |
| 02:22 ET | 200 | 19.6 |
| 02:26 ET | 600 | 19.7 |
| 02:47 ET | 100 | 19.77 |
| 02:49 ET | 1248 | 19.83 |
| 02:51 ET | 200 | 19.87 |
| 02:54 ET | 600 | 19.82 |
| 02:58 ET | 100 | 19.84 |
| 03:00 ET | 201 | 19.89 |
| 03:02 ET | 100 | 19.87 |
| 03:03 ET | 600 | 19.85 |
| 03:14 ET | 200 | 19.98 |
| 03:16 ET | 400 | 19.93 |
| 03:21 ET | 300 | 19.88 |
| 03:23 ET | 100 | 19.89 |
| 03:25 ET | 100 | 19.87 |
| 03:27 ET | 760 | 19.9288 |
| 03:30 ET | 200 | 19.94 |
| 03:34 ET | 300 | 19.92 |
| 03:36 ET | 400 | 19.92 |
| 03:38 ET | 100 | 19.905 |
| 03:39 ET | 300 | 19.93 |
| 03:41 ET | 100 | 19.95 |
| 03:43 ET | 200 | 19.96 |
| 03:45 ET | 200 | 19.96 |
| 03:48 ET | 300 | 19.95 |
| 03:50 ET | 100 | 19.94 |
| 03:52 ET | 700 | 19.97 |
| 03:54 ET | 400 | 19.935 |
| 03:56 ET | 455 | 19.95 |
| 03:57 ET | 800 | 19.96 |
| 03:59 ET | 10925 | 19.98 |
Jun 24, 2022
Mirum Pharmaceuticals Highlights Data Demonstrating Impact of LIVMARLI(R) (maralixibat) on Patients with Alagille Syndrome at European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting, from 8:00AM ET on Friday Jun 24, 2022 by Business Wire
8:00AM ET on Friday Jun 24, 2022 by Business WireMirum Pharmaceuticals Presents New Data at The International Liver Congress(TM) of the European Association for the Study of the Liver (EASL), from 3:00AM ET on Friday Jun 24, 2022 by Business Wire
3:00AM ET on Friday Jun 24, 2022 by Business Wire
Jun 13, 2022
Mirum Pharmaceuticals to Showcase LIVMARLI(R) (maralixibat) Data at EASL and ESPGHAN Annual Congresses, from 8:30AM ET on Monday Jun 13, 2022 by Business Wire
8:30AM ET on Monday Jun 13, 2022 by Business Wire
Jun 10, 2022
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 8:00PM ET on Friday Jun 10, 2022 by Business Wire
8:00PM ET on Friday Jun 10, 2022 by Business Wire
Jun 6, 2022
BRIEF-Mirum Pharmaceuticals Appoints Saira Ramasastry To Board Of Directors, from 8:35AM ET on Monday Jun 06, 2022 by Thomson Reuters
8:35AM ET on Monday Jun 06, 2022 by Thomson Reuters
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mirum Pharmaceuticals Inc | 636.1M | -8.7x | --- |
PureTech Health PLC | 616.7M | -9.8x | --- |
Keros Therapeutics Inc | 675.1M | -9.9x | --- |
ATAI Life Sciences NV | 586.7M | -2.6x | --- |
Cullinan Oncology Inc | 579.0M | -7.2x | --- |
Geron Corp | 630.3M | -4.7x | --- |
Company Information
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of therapies for rare and orphan diseases. The Company's main focus is the development and commercialization of LIVMARLI (maralixibat) oral solution (Livmarli) and Volixibat. Its pipeline consists of rare pediatric indications for Livmarli and orphan adult indications for its second product candidate, Volixibat. Livmarli is an oral solution as a once-daily medicine for cholestatic pruritus in patients with Alagille syndrome (ALGS) one year of age and older. Volixibat, is an oral, minimally absorbed agent designed to inhibit ileal bile acid transporter (IBAT), for the treatment of adult patients with cholestatic liver diseases. The Company is developing volixibat for the treatment of intrahepatic cholestasis of pregnancy (ICP), primary sclerosing cholangitis (PSC), and primary biliary cholangitis (PBC).
Contact Information
- Headquarters
- 950 Tower Ln Ste 1050FOSTER CITY, CA, United States 94404-4251
- Phone
- 650-667-4085
- Fax
- 302-269-3855
Executives
- Chairman of the Board
- Michael Grey
- President, Chief Executive Officer, Co-Founder, Director
- Christopher Peetz
- Chief Financial Officer
- Ian Clements
- Chief Operating Officer
- Peter Radovich
- Chief Development Officer
- Lara Longpre
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $636.1M |
|---|---|
Revenue (TTM) | $32.0M |
Shares Outstanding | 31.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.29 |
Book Value | $3.93 |
P/E Ratio | -8.7x |
Price/Sales (TTM) | 19.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -157.78% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
